For lifecycle management purposes, NCI exclusivity is the mechanism that gives commercial value to indication expansion programs
In doing so, semaglutide also increases levels of satiety and is recognized as beneficial in the treatment of Type 2 diabetes (T2DM)
The FDA is now considering allowing its use in supplements due to its long history of safe use
Document clinical contraindication to semaglutide: Persistent nausea or vomiting preventing dose escalation beyond initial doses, a documented thyroid concern (e.g., personal or family history of MEN 2 or medullary thyroid carcinoma), or another clinically documented intolerance can serve as the basis for the exception request
Shifting Clinical Conversations We know that worry about drug testing and lab surprises is exhausting
The potential advantage of GLP-1 therapy in ADHD contexts may lie in addressing comorbid weight gain, a common side effect of stimulant medications